Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK-105 plus anlotinib as first-line therapy for advanced esophageal cancer
ChiCTR2100047085Phase 4Recruiting
- Sponsor
- Luohe Central Hospital
- Start
- Jul 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of penpulimab and anlotinib in esophageal cancer, sponsored by Luohe Central Hospital. Primary endpoint: Progression-free survival. Started Jul 2021; status: recruiting.
02
Drugs
penpulimabanlotinib
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2100047085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047085.